These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30111966)

  • 61. Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada.
    Bentley C; Costa S; Burgess MM; Regier D; McTaggart-Cowan H; Peacock SJ
    BMC Health Serv Res; 2018 May; 18(1):339. PubMed ID: 29739463
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
    Kennedy J; Morgan S
    Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey.
    Dragojlovic N; Rizzardo S; Bansback N; Mitton C; Marra CA; Lynd LD
    Patient; 2015 Feb; 8(1):93-101. PubMed ID: 25586645
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworks.
    Hyshka E; Anderson-Baron J; Karekezi K; Belle-Isle L; Elliott R; Pauly B; Strike C; Asbridge M; Dell C; McBride K; Hathaway A; Wild TC
    Harm Reduct J; 2017 Jul; 14(1):50. PubMed ID: 28747183
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Promoting equitable global health research: a policy analysis of the Canadian funding landscape.
    Plamondon K; Walters D; Campbell S; Hatfield J
    Health Res Policy Syst; 2017 Aug; 15(1):72. PubMed ID: 28851388
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Barriers and Facilitators for Primary Care Reform in Canada: Results from a Deliberative Synthesis across Five Provinces.
    Levesque JF; Haggerty JL; Hogg W; Burge F; Wong ST; Katz A; Grimard D; Weenink JW; Pineault R
    Healthc Policy; 2015 Nov; 11(2):44-57. PubMed ID: 26742115
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Status report. Canadian strategy for cancer control.
    Luciani S; Berman NJ
    Chronic Dis Can; 2000; 21(1):23-5. PubMed ID: 10813690
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pan-Canadian review of cancer drugs will not be binding on provinces.
    Vogel L
    CMAJ; 2010 Jun; 182(9):887-8. PubMed ID: 20479048
    [No Abstract]   [Full Text] [Related]  

  • 69. LEGITIMACY OF MEDICINES FUNDING IN THE ERA OF ACCELERATED ACCESS.
    Pace J; Pearson SA; Lipworth W
    Int J Technol Assess Health Care; 2017 Jan; 33(6):700-707. PubMed ID: 28893332
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding.
    Sinclair S; Hagen NA; Chambers C; Manns B; Simon A; Browman GP
    Health Policy; 2008 May; 86(2-3):381-90. PubMed ID: 18243395
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.
    Grootendorst P
    Can J Clin Pharmacol; 2002; 9(2):79-99. PubMed ID: 12172588
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Regulators in access to anticancer drugs in Canada].
    Côté A; Keating B; Parent M; Simard G
    Sante Publique; 2015; 27(4):515-27. PubMed ID: 26751926
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
    Franken MG; Gaultney JG; Blommestein HM; Huijgens PC; Sonneveld P; Redekop WK; Uyl-de Groot CA
    Value Health; 2014 Mar; 17(2):245-53. PubMed ID: 24636383
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Priority-setting decisions for new cancer drugs: a qualitative case study.
    Martin DK; Pater JL; Singer PA
    Lancet; 2001 Nov; 358(9294):1676-81. PubMed ID: 11728542
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Research evidence and policy: qualitative study in selected provinces in South Africa and Cameroon.
    Naude CE; Zani B; Ongolo-Zogo P; Wiysonge CS; Dudley L; Kredo T; Garner P; Young T
    Implement Sci; 2015 Sep; 10():126. PubMed ID: 26334760
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Stop-Smoking Medication Use, Subsidization Policies, and Cessation in Canada.
    White CM; Rynard VL; Reid JL; Ahmed R; Burkhalter R; Hammond D
    Am J Prev Med; 2015 Aug; 49(2):188-98. PubMed ID: 26033348
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Abortion health services in Canada: Results of a 2012 national survey.
    Norman WV; Guilbert ER; Okpaleke C; Hayden AS; Steven Lichtenberg E; Paul M; White KO; Jones HE
    Can Fam Physician; 2016 Apr; 62(4):e209-e217. PubMed ID: 28192276
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Analysis on funds application of community based organizations involved in HIV/AIDS response and government financial investment in China, 2014].
    Zhang G; Zhu YX; Wang P; Liu P; Li JF; Sha S; Yang WZ; Li H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Mar; 51(3):232-236. PubMed ID: 28260337
    [No Abstract]   [Full Text] [Related]  

  • 80. Barriers to participation in clinical trials: a physician survey.
    Mahmud A; Zalay O; Springer A; Arts K; Eisenhauer E
    Curr Oncol; 2018 Apr; 25(2):119-125. PubMed ID: 29719427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.